Ojala JP - Search Results

1

Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.

Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Vuorio AF, et al. Among authors: ojala jp. J Intern Med. 1995 Jan;237(1):43-8. doi: 10.1111/j.1365-2796.1995.tb01138.x. J Intern Med. 1995. PMID: 7830029

2

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ. Ojala JP, et al. J Intern Med. 1991 Nov;230(5):397-405. doi: 10.1111/j.1365-2796.1991.tb00464.x. J Intern Med. 1991. PMID: 1940775 Clinical Trial.

3

Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia.

Tikkanen MJ, Ojala JP, Helve E. Tikkanen MJ, et al. Among authors: ojala jp. Eur J Clin Pharmacol. 1991;40 Suppl 1:S23-5. Eur J Clin Pharmacol. 1991. PMID: 2044638

4

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.

Ojala JP, Helve E, Tikkanen MJ. Ojala JP, et al. Cardiology. 1990;77 Suppl 4:39-49. doi: 10.1159/000174682. Cardiology. 1990. PMID: 2073671 Clinical Trial.

5

Use of polymerase chain reaction to detect heterozygous familial hypercholesterolemia.

Keinänen M, Ojala JP, Helve E, Aalto-Setälä K, Kontula K, Kovanen PT. Keinänen M, et al. Among authors: ojala jp. Clin Chem. 1990 Jun;36(6):900-3. Clin Chem. 1990. PMID: 2357830

6

Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.

Ojala JP, Helve E, Karjalainen K, Tarkkanen A, Tikkanen MJ. Ojala JP, et al. Atherosclerosis. 1990 May;82(1-2):85-95. doi: 10.1016/0021-9150(90)90147-b. Atherosclerosis. 1990. PMID: 2360923

7

Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.

Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Laaksonen R, et al. Among authors: ojala jp. Eur J Clin Pharmacol. 1994;46(4):313-7. doi: 10.1007/BF00194398. Eur J Clin Pharmacol. 1994. PMID: 7957515 Clinical Trial.

8

Screening of the 3' two-thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients report of six new genetic variants.

Ilmonen M, Ebeling T, Viikari J, Ojala JP, Tikkanen MJ. Ilmonen M, et al. Among authors: ojala jp. Atherosclerosis. 1997 Feb 10;128(2):191-9. doi: 10.1016/s0021-9150(96)05990-4. Atherosclerosis. 1997. PMID: 9050776

9

A Randomized, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial.

Ojala J, Vanhanen J, Harno H, Lioumis P, Vaalto S, Kaunisto MA, Putaala J, Kangasniemi M, Kirveskari E, Mäkelä JP, Kalso E. Ojala J, et al. Neuromodulation. 2022 Jun;25(4):538-548. doi: 10.1111/ner.13496. Epub 2022 Feb 2. Neuromodulation. 2022. PMID: 35670063 Free article. Clinical Trial.

10

[No title available]

[No authors listed] [No authors listed] PMID: 34370364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters